Axsome Therapeutics (AXSM) Non-Current Debt (2015 - 2026)

Axsome Therapeutics has reported Non-Current Debt for 12 years, with the latest figure at $117.8 million in Q1 2026.

• Quarterly Non-Current Debt fell 35.02% year-over-year to $117.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $117.8 million (down 35.02% YoY) and the FY2025 annual result came in at $117.7 million, down 34.84% from the prior year.
• Non-Current Debt was little changed at $117.8 million in Q1 2026 per AXSM's latest filing, from $117.7 million in the prior quarter.
• Over five years, Non-Current Debt peaked at $181.4 million in Q1 2025 and troughed at $49.3 million in Q1 2022.
• A 5-year average of $134.2 million and a median of $117.8 million in 2026 frame the typical range for Non-Current Debt.
• The sharpest annual moves came in 2023 and 2024: Non-Current Debt surged 199.35% in 2023, then sank 54.92% in 2024.
• Over 5 years, Non-Current Debt stood at $94.3 million in 2022, then soared by 88.92% to $178.1 million in 2023, then advanced by 1.48% to $180.7 million in 2024, then plunged by 34.84% to $117.7 million in 2025, then grew by 0.09% to $117.8 million in 2026.
• According to Business Quant data, Non-Current Debt over the past three periods registered $117.8 million, $117.7 million, and $117.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.